Advertisement

Promising Anti-HIV Compounds in Preclinical or Early Clinical Development

  • Charles Litterst
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

In the past several years the focus of drug discovery and development for HIV infection has shifted from nucleoside inhibitors of reverse transcriptase (RT) to non-nucleoside RT inhibitors (NNRTI) and most recently to protease inhibitors, all of which already have been discussed at this meeting. Among the other virus-specific targets for therapeutic intervention, several are recognized as having potential for clinical success and thus are the focus of extensive preclinical and/or clinical investigations. The compounds to be discussed here were selected because of similarities in viral target or because of ongoing clinical interest as indicated by clinical trials in progress. Selection for discussion in this paper does not imply endorsement or support by the Division of AIDS, NIAID.

Keywords

Human Immunodeficiency ViruS Type Antisense Oligonucleotide Infected Cell Culture Tumor necrosIs Factor Antisense Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ashom, B. Moss, E. Berger, Anti-HIV effects of CD4-Pseudomonas exotoxin on human lymphocyte and monocyte/macrophage cell lines. Ann NY Acad. Sci. (1990) 616: 149–154.CrossRefGoogle Scholar
  2. 2.
    Ashorn, B. Moss, J. Weinstein, et. al., Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc. Nat. Acad. Sci. USA, (1990) 87: 8889–8893.CrossRefGoogle Scholar
  3. 3.
    Kennedy, B. Moss, E. Berger. Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Virol. (1993) 192: 375–379.CrossRefGoogle Scholar
  4. 4.
    Wyatt, T. Vickers, J. Roberson, et. al., Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Nat. Acad. Sci. USA (1994) 91: 1356–1360.CrossRefGoogle Scholar
  5. 5.
    Williamson, Guanine Quartets. Curr. Opin. Struct. Biol. (1993) 3: 357–362.CrossRefGoogle Scholar
  6. 6.
    Yahi, J. Fantini. K. Mabrouk, et. al. Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages. J. Virol. (1994): 68: 5714–5720.Google Scholar
  7. 7.
    Poli, A. Kinter, J. Justement, et. al. Tumor necrosis factor a. functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc. Nat. Acad. Sci. USA (1990) 87: 782–785.CrossRefGoogle Scholar
  8. 8.
    Makonkawkeyoon, R. Limson-Pobre, A. Moreira, et_ al., Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Nat. Acad. Sci. USA (1993) 90: 5974–5978.CrossRefGoogle Scholar
  9. 9.
    Fazely, B. Dezube, J. Allen-Ryan, et. al.. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood (1991) 77: 1653–1658.PubMedGoogle Scholar
  10. 10.
    Dezube, J. Eder, A. Pardee. Phase I trial of escalating pentoxifylline dose with constant thiotepa (1990) Cancer Res. 50: 6806–6810.Google Scholar
  11. 11.
    Dezube, A. Pardee, B. Chapman, et al., Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. (1993) J. AIDS 6: 787–794.Google Scholar
  12. 12.
    Zamecnik, S. Agrawal, Multiple roles of oligonucleotides in the regulation of genetic expression. IN: New Leads and Targets in Drug Research (P.Krogsgaard-Larsen, S.B. Christensen, H. Kofod, eds), Munksgaard, Copenhagan, pp 48–56, 1992_Google Scholar
  13. 13.
    Lisziewicz, D. Sun, M. Klotman, et. al., Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: An in vitro model for treatment. Proc. Nat. Acad. Sci. USA (1992) 89: 11209–11213.PubMedCrossRefGoogle Scholar
  14. 14.
    Agrawal, P. Sarin, M. Zamecnik, et. al., Cellular uptake and anti-HIV activity of oligonucleotides and their analogs. IN: Gene regulation: Biology of antisense RNA and DNA (R. Erickson, F. Izant, eds). Raven Press, New York, pp. 273–283, 1992.Google Scholar
  15. 15.
    Zamecnik, J. Aghajanian, M. Zamecnik, et. al., Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. Proc. Nat. Acad. Sci. USA (1994) 91: 3156–3160.CrossRefGoogle Scholar
  16. 16.
    Lisziewicz, D. Sun, V. Metelev, et. al., Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc. Nat. Acad. Sci. USA (1993) 90: 3860–3864.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Charles Litterst

There are no affiliations available

Personalised recommendations